Recently, Associate Professor Li Meixian’s research group at Nantong University reported their work in e-Polymers (De Gruyter), a SCI-indexed polymer journal. Plasma treatment can tailor the surface microstructure of ePTFE membranes, where polydopamine (PDA) and heparin are successfully immobilized. After modification, the membranes show enhanced hydrophilicity, suppressed platelet and protein adhesion, good anticoagulant property, and acceptable hemolysis ratio complying with biosafety standards. This approach is viable and easy for large-scale production, which provides an effective pathway for functionalizing ePTFE for wider biomedical applications.
Due to the impacts of lifestyle and dietary patterns, the prevalence of vascular-associated diseases has risen markedly. Accordingly, vascular replacement surgery has become an essential therapeutic approach. For clinical application, artificial vascular grafts are required to satisfy rigorous criteria in terms of biocompatibility, mechanical strength, antithrombotic performance and compliance.
At present, widely adopted graft materials cover polyurethane (PU), polycaprolactone (PCL), polyethylene terephthalate (PET) and expanded polytetrafluoroethylene (ePTFE). ePTFE is distinguished by its mechanical performance, chemical inertness and excellent long-term stability in vivo. However, its hydrophobic and bioinert surface inhibits endothelial cell adhesion and induces thrombosis, which restricts its utilization for small-diameter vascular grafts.
Under physiological conditions, the luminal surface of blood vessels is lined by vascular endothelial cells. Such cells actively synthesize and release diverse bioactive mediators to restrain platelet adhesion and avert coagulation. Moreover, an intact endothelium inhibits the proliferation of vascular smooth muscle cells, reducing the incidence of intimal hyperplasia. When implanted grafts have no endothelial barrier, protein adsorption may be initiated, subsequently inducing platelet adhesion, activation and aggregation. This cascade can cause postoperative complications including early thrombus formation and restenosis. Ample evidence indicates that hydrophilic substrates facilitate endothelial cell growth. However, ePTFE possesses a highly inert surface without reactive functional groups, presenting strong hydrophobicity. This characteristic restricts its wider adoption in medical applications.
To tackle the extreme surface inertness and intrinsic hydrophobicity of ePTFE, oxygen plasma or air plasma treatment integrated with PDA and HEP is proposed for surface modification in this work. The strategy achieves prominent enhancement in the biocompatibility and hemocompatibility of ePTFE membranes. The key findings are summarized below:
SEM observations indicate that plasma treatment time enables effective regulation of the surface morphology of ePTFE membranes. With prolonged treatment duration, the microcracks, porous structure and surface roughness of the material change in a controllable manner. FTIR and water contact angle tests verify that hydrophilic functional groups are successfully incorporated on ePTFE surfaces via oxygen plasma, PDA and HEP modification, leading to a remarkable enhancement in hydrophilicity. In addition, oxygen plasma outperforms air plasma in modification efficiency. Quantitative carboxyl group analysis further confirms the immobilization of HEP on the membrane. Biological assays show that PDA grafting markedly inhibits platelet adhesion, and the subsequent HEP functionalization further strengthens antithrombotic properties. Reduced BSA adsorption and ultra-low hemolysis rate demonstrate excellent hemocompatibility. Mechanical characterization suggests that plasma treatment and surface modification exert minimal influence on the tensile strength and elongation at break of ePTFE membranes. Accordingly, the material maintains desirable mechanical stability along with superior surface and biological properties, and holds great potential as a vascular graft material.
In conclusion, the plasma treatment combined with PDA/HEP modification strategy reported herein successfully mitigates the high surface inertness and weak hydrophilicity of ePTFE membranes. The modified membranes exhibit superior hydrophilicity, antithrombotic properties and biocompatibility. This study provides a route for translation toward next-generation blood-contacting medical devices, such as small-caliber vascular grafts, endovascular stent graft coverings and patent foramen ovale (PFO) closure devices. Additional characterizations will be performed in follow-up investigations to generate practical insights for ePTFE-based small-diameter vascular grafts.
About Us
Introduction Culture History HonorNews
News Article VideoService
After-sale ServiceNavigation
ProductsSolutionContact Us
400-6505-735
CIF WeChat Service Account
CIF Tiktok